Poster Presentations Session I
Poster Presentations Session I Monday, May 21, 2018
POSTERS SET-UP: 8:15 AM - 8:30 AM
POSTERS DISPLAY HOURS: 8:30 AM - 2:00 PM
POSTER AUTHOR DISCUSSION: 1:00 PM - 2:00 PM
POSTERS DISMANTLE: 2:00 PM


Poster display locations are shown below the poster codes
NEUROLOGICAL DISORDERS - Clinical Outcomes Studies
PND1
I20
RISK OF SUBSEQUENT MIGRAINE EVENTS AFTER TREATING MIGRAINE WITH OPIOIDS AMONG MISSISSIPPI DIVISION OF MEDICAID BENEFICIARIES
Gangan N1, Pittman E1, Banahan III B2, Noble S3
1Center for Pharmaceutical Marketing and Management, University of Mississippi, University, MS, USA, 2Department of Pharmacy Administration, University of Mississippi School of Pharmacy, University, MS, USA, 3Mississippi Division of Medicaid, Jackson, MS, USA

PND2
I21
RISK OF DEATH FROM THE USE OF ATYPICAL ANTIPSYCHOTIC DRUGS FOR THE TREATMENT OF NEUROPYSCHIATRIC SYMPTOMS OF DEMENTIA: A NETWORK META-ANALYSIS
Yunusa I1, Eguale T1, Garba AE2, Alsumali A1
1MCPHS University, Boston, MA, USA, 2Saint Louis University, St. Louis, MO, USA

PND3
I22
INOTERSEN IMPROVES QUALITY OF LIFE AND NEUROPATHY IN PATIENTS WITH HEREDITARY TRANSTHYRETIN (HATTR) AMYLOIDOSIS WITH POLYNEUROPATHY: RESULTS OF THE PHASE 3 STUDY NEURO-TTR
Berk JL1, Coelho T2, Wang AK3, Waddington-Cruz M4, Polydefkis MJ5, Dyck PJ6, Scheinberg M7, Plante-Bordeneuve V8, Barroso F9, Adams D10, Brannagan TH11, Whelan C12, Merlini G13, Drachman BM14, Heitner SB15, Conceicao I16, Schmidt H17, Vita G18, Campistol JM19, Gorevic P20, Monia BP21, Hughes SG21, Kwoh J21, Jung B21, Ackermann EJ21, Gertz M6, Benson MD22
1Boston University, Boston, MA, USA, 2Centro Hospitalar do Porto, Porto, Portugal, 3University of California, Irvine, Orange, CA, USA, 4Federal University of Rio de Janeiro University Hospital, Rio de Janeiro, Brazil, 5Johns Hopkins University, Baltimore, MD, USA, 6Mayo Clinic, Rochester, MN, USA, 7Associação de Assistência a Criança Deficiente, Sao Paolo, Brazil, 8CHU Henri Mondor, Creteil, France, 9FLENI, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, 10CHU Bicêtre, Universite Paris-Sud, Le Kremlin-Bicêtre, France, 11Columbia University Medical Center, New York, NY, USA, 12University College London—National Amyloidosis Centre, London, UK, 13Amyloidosis Center, IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy, 14University of Pennsylvania, Philadelphia, PA, USA, 15Oregon Health and Science University, Portland, OR, USA, 16Hospital de Santa Maria-CHLN, and IMM Faculty of Medicine, UL., Lisbon, Portugal, 17Universitätsklinikum Münster, Münster, Germany, 18University of Messina, Messina, Italy, 19Hospital Clinic, University of Barcelona, Barcelona, Spain, 20Mount Sinai Medical Center, New York, NY, USA, 21Ionis Pharmaceuticals, Carlsbad, CA, USA, 22Indiana University School of Medicine, Indianapolis, IN, USA

PND4
WITHDRAWN

PND5
I23
THE CLINICAL VALUE OF EARLY DIAGNOSIS TESTS FOR THE LONG-TERM MANAGEMENT OF DEMENTIA
Tafazzoli A, Kansal AR
Evidera, Bethesda, MD, USA

PND6
I24
UNMET NEEDS IN THE MANAGEMENT OF HYPOACTIVE SEXUAL DESIRE DISORDER IN PREMENOPAUSAL WOMEN
Simon JA1, Athavale A2, Ravindranath R2, Hadker N2, Lim-Watson M3
1George Washington University and Women’s Health & and Research Consultants, Washington, DC, USA, 2Trinity Partners, Waltham, MA, USA, 3AMAG Pharmaceuticals, Inc., Waltham, MA, USA

PND7
J1
A PROSPECTIVE CLINICAL OBSERVATIONAL STUDY ON ASSESSMENT OF RISK FACTORS, DIAGNOSIS AND PRESCRIBING PATTERNS OF MEDICATIONS FOR MIGRAINE
Om Prakash P1, Mahender Reddy V2, Preethi M2, Sirajuddin SK2, Prashanth Reddy P2
1Sri Sri Neuro Clinic, Warangal, India, 2St Peter's Institute of pharmaceutical sciences, Warangal, India

PND8
J2
REAL-WORLD OUTCOMES AND MEDICATION ADHERENCE TO DISEASE MODIFYING THERAPIES (DMTS) AMONG PATIENTS WITH MULTIPLE SCLEROSIS (MS)
Grassi DM1, Graham J1, Ye X2, Maeng D1, Frusciante K1, Nathanson DC1, Burton M1, Wright E1, Gomes J2, Bao Y2
1Geisinger, Danville, PA, USA, 2AbbVie, Inc., Mettawa, IL, USA

PND9
J3
EFFECTIVENESS OF KOREAN MEDICINE THERAPY FOR PARKINSON’S DISEASE MANAGEMENT: NATIONAL HEALTH INSURANCE SERVICE-NATIONAL SAMPLE COHORT (NHIS-NSC)
Woo Y1, Hyun MK2
1Dongguk University Graduate School, Seoul, Korea, Republic of (South), 2Dongguk University, Gyeongju-si, Korea, Republic of (South)

PND10
J4
COMPARATIVE SAFETY OF SLEEP PRESCRIPTIONS AND SUICIDE ATTEMPTS IN VETERANS
Lavigne JE1, Hur K2, Kane CP1, Au A2, Bishop T1, Pigeon W1
1US Department of Veterans Health Affairs, Canandaigua, NY, USA, 2US Department of Veterans Health Affairs, Hines, IL, USA

PND11
J5
WITHDRAWN

PND12
J6
IMMUNOMODULATORS AND IMMUNOSUPPRESSANTS FOR PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS: A NETWORK META-ANALYSIS
Lucchetta RC1, Tonin FS1, Borba HH1, Leonart LP1, Ferreira VL1, Bonetti AF1, Riveros BS1, Becker J2, Pontarolo R1, Fernandez-Llimós F3, Wiens A1
1Federal University of Parana, Curitiba, Brazil, 2Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Brazil, 3Research Institute for Medicines (iMed.ULisboa), Lisboa, Portugal

PND13
J7
COMPARISON OF ALL-CAUSE MORTALITY AND ALL-CAUSE HOSPITALIZATION RISK FOR MEDICATIONS TO TREAT ALZHEIMER’S DISEASE
Bhattacharjee S1, Patanwala A2, Malone DC1, Lee JK1, Knapp S2, Lo-Ciganic W2, Warholak T2, Burke WJ3
1University of Arizona, Tucson, AZ, USA, 2The University of Arizona, Tucson, AZ, USA, 3Banner Alzheimer's Institute, Phoenix, AZ, USA

PND14
J8
WITHDRAWN

PND15
J9
SIZING OF THE MIGRAINE POPULATION TREATED WITH PREVENTIVE MEDICATIONS FOR MIGRAINE
Burrell ER1, Mues KE1, Xue F1, Buse DC2, Lipton RB2, Chia VM1
1Amgen Inc., Thousand Oaks, CA, USA, 2Albert Einstein College of Medicine, Bronx, NY, USA

PND16
J10
ATYPICAL ANTIPSYCHOTIC USE AMONG LONG-TERM CARE RESIDENTS WITH PARKINSON'S DISEASE AND COMORBID DEPRESSION
Chekani F1, Johnson ML1, Chen H1, Sherer JT1, Holmes HM2, Aparasu RR1
1University of Houston, Houston, TX, USA, 2The University of Texas Health Science Center, Houston, TX, USA

PND17
J11
DIFFERENCES IN ALZHEIMER’S DISEASE PROTECTIVENESS AMONG RENIN-ANGIOTENSIN SYSTEM ACTING ANTI-HYPERTENSIVE PRESCRIPTION DRUGS
Barthold D
University of Washington, Seattle, WA, USA

PND18
J12
PREVALENCE, DISEASE BURDEN AND UNMET NEEDS OF PATIENTS WITH ESSENTIAL TREMOR: A SYSTEMATIC REVIEW AND META-ANALYSIS
Yunusa I1, Abraham P2, Alsumali A1, Eguale T1
1MCPHS University, Boston, MA, USA, 2Bristol-Myers Squibb, Lawrenceville, NJ, USA

PND19
J13
ASSOCIATION BETWEEN EXENATIDE/Β2AR USE AND PARKINSON’S DISEASE RISK IN MEDICARE POPULATION
Zhou B, Romley JA
University of Southern California, Los Angeles, CA, USA

PND20
J14
MODELED SURVIVAL GAINS OF PATIENTS WITH CYSTIC FIBROSIS (CF) AGED ≥12 YEARS HOMOZYGOUS FOR THE F508DEL MUTATION TREATED WITH THE CF TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATOR (CFTRM) TEZACAFTOR/IVACAFTOR (TEZ/IVA)
Lopez A1, Suthoff E1, Chandler C2, Liou T3, Konstan M4, Pelligra C2, Ward A2, Rubin J1, McGarry L1
1Vertex Pharmaceuticals Incorporated, Boston, MA, USA, 2Evidera, Waltham, MA, USA, 3University of Utah, Salt Lake City, UT, USA, 4Case Western Reserve University School of Medicine and Rainbow Babies and Children’s Hospital, Cleveland, OH, USA

NEUROLOGICAL DISORDERS - Cost Studies
PND21
J15
WITHDRAWN

PND22
J16
BUDGET IMPACT ANALYSIS OF CLADRIBINE TABLETS FOR TREATMENT OF PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN BULGARIA
Djambazov S1, Slavchev G1, Dineva T2, Panayotov P2, Vekov T3
1HTA Ltd., Sofia, Bulgaria, 2Merck Bulgaria EAD, Sofia, Bulgaria, 3Medical University Pleven, Pleven, Bulgaria

PND23
J17
PROGRESSIVE PRIMARY MULTIPLE SCLEROSIS (PPMS): WHERE DISABILITY IS GROWING AND TREATMENT IS ABSENT.
Moreno-Silva NA, SantaMaría A, Díaz-Toro YR
Productos Roche S.A. Colombia, Bogotá, Colombia

PND24
J18
INDIRECT COSTS OF PARKINSON DISEASE HEALTH CARE IN THE NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY IN THE MEXICO CITY
Rodriguez Violante M1, Cervantes Arriaga A1, Guzmán-Vázquez S2, Ponce R3, Soto Molina H3
1Instituto Nacional de Neurología y Neurocirugía, Ciudad de Mexico, Mexico, 2H S Estudios Farmacoeconomicos S A de CV, Mexico City, Mexico, 3HS Estudios Farmacoeconómicos S.A. de C.V., Mexico City, Mexico

PND25
J19
A COST-EFFECTIVENESS ANALYSIS OF VORETIGENE NEPARVOVEC FOR VISION LOSS DUE TO BIALLELIC RPE65-MEDIATED INHERITED RETINAL DISEASE
Zimmermann MR1, Lubinga SJ1, Rind D2, Chapman RH2, Carlson JJ1
1University of Washington, Seattle, WA, USA, 2Institute for Clinical and Economic Review, Boston, MA, USA

PND26
J20
COST-EFFECTIVENESS OF DONEPEZIL IN THE TREATMENT OF PATIENTS WITH ALZHEIMER'S DISEASE: AN UPDATE
Chyr LC, Yapici HO, Padula WV
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

PND27
J21
COST-EFFECTIVENESS OF DACLIZUMAB VERSUS INTERFERON BETA-1A IN THE TREATMENT OF PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN THE UNITED STATES
Rao D1, Heidari E2, Kamal KM2, Dashputre AA3
1Duquesne University, School of Pharmacy, Pittsburgh, PA, USA, 2Duquesne University School of Pharmacy, Pittsburgh, PA, USA, 3University of Tennessee, Memphis, TN, USA

PND28
J22
MODELING THE REDUCTION IN THE CLINICAL BURDEN OF MIGRAINE WITH ERENUMAB TREATMENT
Porter JK1, Di Tanna GL1, Lipton RB2, Brennan A3, Palmer S4, Sapra S5, Villa G1
1Amgen (Europe) GmbH, Zug, Switzerland, 2Albert Einstein College of Medicine, Bronx, NY, USA, 3University of Sheffield, Sheffield, UK, 4University of York, Heslington, York, UK, 5Amgen Inc, Thousand Oaks, CA, USA

PND29
J23
A COST EFFECTIVENESS ANALYSIS (CEA) OF PHENYTOIN (PHT) VERSUS LEVETIRACETAM (LEV) FOR EARLY SEIZURE PHARMACOPROPHYLAXIS AFTER TRAUMATIC BRAIN INJURY (TBI) FROM A US INSTITUTIONAL PERSPECTIVE: AN UPGRADE OF A COST MINIMIZATION ANALYSIS (CMA)
Hariharan D, Daniels K, Kodeih R, Amamoo J, Sultan I, Rittenhouse B
MCPHS University, Boston, MA, USA

PND30
J24
COST-EFFECTIVENESS ANALYSIS OF CLADRIBINE TABLETS FOR TREATMENT OF PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN BULGARIA
Djambazov S1, Slavchev G1, Dineva T2, Panayotov P2, Vekov T3
1HTA Ltd., Sofia, Bulgaria, 2Merck Bulgaria EAD, Sofia, Bulgaria, 3Medical University Pleven, Pleven, Bulgaria

PND31
K1
WITHDRAWN

PND32
K2
COST-EFFECTIVENESS OF TREATING ROMANIAN POST-STROKE PATIENTS WITH UPPER LIMB SPASTICITY WITH INCOBOTULINUMTOXIN-A AGAINST CONVENTIONAL THERAPY
Turcu-Stiolica A1, Subtirelu M2
1University of Medicine and Pharmacy of Craiova, Craiova, Romania, 2University of Medicine and Pharmacy, Craiova, Romania

PND33
K3
COMPARING OUTCOMES BETWEEN FIXED AND FLEXIBLE TREATMENT INTERVALS WITH BOTULINUM NEUROTOXINS TYPE A IN THE MANAGEMENT OF BLEPHAROSPASM AND CERVICAL DYSTONIA – A COST-EFFECTIVENESS ANALYSIS FROM THE ROMANIAN PERSPECTIVE
Turcu-Stiolica A1, Tilden D2, Guarnieri C2, Subtirelu M3
1University of Medicine and Pharmacy of Craiova, Craiova, Romania, 2THEMA Consulting Pty Ltd, Pyrmont, Australia, 3University of Medicine and Pharmacy, Craiova, Romania

PND34
K4
COST-UTILITY ANALYSIS OF ORAL SUMATRIPTAN VERSUS ORAL ERGOTAMINE/CAFFEINE IN THE TREATMENT OF ACUTE MIGRAINE ATTACKS
Ike C, Devine B
University of Washington, Seattle, WA, USA

PND35
K5
QUANTIFYING THE MONITORING BURDEN OF MULTIPLE SCLEROSIS (MS) TREATMENT IN THE UNITED KINGDOM (UK): FEASIBILITY PHASE FOR AN OBSERVATIONAL TIME AND MOTION (T&M) STUDY
De Cock E1, Palacios L2, Harty G3, Mokiou S4
1Syneos Health, Barcelona, Spain, 2Syneos Health, Madrid, Spain, 3EMD Serono, Billerica, MA, USA, 4Merck Serono Ltd, Feltham, UK

PND36
K6
WITHDRAWN

PND37
K7
RESOURCE USE RELATED TO PEDIATRIC LOWER LIMB SPASTICITY IN CANADA: PHYSICIAN QUESTIONNAIRE
Powell LC1, Johnston KM1, Liovas A2, Chong M3, Danchenko N4, Dinet J4
1Broadstreet Health Economics & Outcomes Research, Vancouver, BC, Canada, 2Ipsen Biopharmaceuticals Canada, Mississauga, ON, Canada, 3Ipsen Canada, Mississauga, ON, Canada, 4Ipsen Global, Boulogne-Billancourt, France

NEUROLOGICAL DISORDERS - Patient-Reported Outcomes & Patient Preference Studies
PND38
K8
A SYSTEMATIC REVIEW OF DISCRETE CHOICE EXPERIMENT AND CONJOINT ANALYSIS IN MEASURING PATIENTS’ PREFERENCES FOR MULTIPLE SCLEROSIS TREATMENTS
Wanishayakorn T1, Cejudo T2, Nimdet K3, Chaiyakunapruk N4, Ngorsuraches S5
1Prince of Songkla University, Hat Yai, Thailand, 2Université Claude Bernard Lyon 1, Lyon, France, 3Suratthani Provincial Public Health Office, Surat thani, Thailand, 4Naresuan University, Phitsanulok, Thailand, 5South Dakota State University, Brookings, SD, USA

PND39
K9
SOMETHING IS BETTER THAN NOTHING: THE VALUE OF ACTIVE INTERVENTION ON STATED PREFERENCES FOR TREATMENTS TO DELAY ONSET OF ALZHEIMER’S DISEASE SYMPTOMS
Johnson FR1, Disantostefano R2, Reed SD3, Yang J4, Levitan B5
1School of Medicine, Duke University, Durham, NC, USA, 2Janssen R&D, Titusville, NJ, USA, 3Duke School of Medicine, Durham, NC, USA, 4Duke Clinical Research Institute, Durham, NC, USA, 5Janssen Research & Development, Titusville, NJ, USA

PND40
K10
ASSESSMENT OF THE BURDEN OF MULTIPLE SCLEROSIS ON FAMILY CAREGIVERS BY PATIENT DISABILITY SEVERITY
Yang E, Yeh W, Engmann NJ, Xu Y, Julian L
Genentech, Inc., South San Francisco, CA, USA

PND41
K11
SELF-REPORTED INSOMNIA SYMPTOMS AND HEALTH RELATED QUALITY OF LIFE IN THE US ADULT POPULATION
Morlock A, Dobrescu R
Acumen Health Research Institute, Ann Arbor, MI, USA

PND42
K12
WITHDRAWN

NEUROLOGICAL DISORDERS - Health Care Use & Policy Studies
PND43
K13
A SYSTEMATIC LITERATURE REVIEW TO ASSESS THE CURRENT EVIDENCE LANDSCAPE FOR DIGITAL BEHAVIOUR INTERVENTIONS IN MULTIPLE SCLEROSIS (MS)
Webb N1, Hudson P1, Palencia R2
1DRG Abacus, Bicester, UK, 2Merck KGaA, Darmstadt, Germany

PND44
K14
EFFECTS OF GALCANEZUMAB ON HEALTHCARE RESOURCE UTILIZATION AND ACUTE MEDICATION USE IN PATIENTS WITH MIGRAINE: RESULTS FROM TWO GLOBAL PHASE 3 CLINICAL TRIALS
Ford JH, Foster SA, Detke HC, Stauffer VL, Ruff DD, Aurora SK
Eli Lilly and Company, Indianapolis, IN, USA

PND45
K15
UTILIZATION, SPENDING, AND PRICES TRENDS FOR ANTI-EPILEPTIC DRUGS (AEDS) IN THE U.S. MEDICAID PROGRAMS: EMPIRICAL DATA ANALYSIS FROM 2010 TO 2016
Yue X, Guo JJ
University of Cincinnati, Cincinnati, OH, USA

PND46
K16
PREDICTIVE MODELLING FOR SECONDARY PREVENTION OF ALZHEIMER’S DISEASE: ETHICAL CONCERNS AND SOCIAL IMPLICATIONS BASED ON TARGETED, NARRATIVE LITERATURE REVIEW
Angehrn Z1, Karcher H1, de Reydet de Vulpillieres F2, Nordon C3
1Analytica LASER, London, UK, 2NOVARTIS PHARMA AG, Basel, Switzerland, 3LASER, Paris, France

PND47
K17
DISPARITY IN RECEIVING DIAGNOSTIC WORKUP AND TREATMENT AMONG CHILDREN WITH REFRACTORY EPILEPSY
Pan I, Lam S
Baylor College of Medicine/Texas Children's Hospital, Houston, TX, USA

PND48
K18
ECONOMIC BURDEN OF DIAGNOSED CHRONIC MIGRAINE AND DIAGNOSED EPISODIC MIGRAINE PATIENTS IN A LARGE US HEALTH INSURER’S POPULATION
Marcus S1, Shewale AR2, Doshi JA3, Young W4, Yu JS2, Pavlovic JM5, Viswanathan HN2
1University of Pennsylvania, Philiadelphia, PA, USA, 2Allergan plc, Irvine, CA, USA, 3University of Pennsylvania, Philadelphia, PA, USA, 4Thomas Jefferson University, Philiadelphia, PA, USA, 5Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA

PND49
K19
INCREASED HEALTHCARE UTILIZATION IN DEMENTIA SUBTYPES PRIOR TO DIAGNOSIS
Albrecht J1, Hanna ML2, Kim D2, Perfetto EM2
1University of Maryland, Baltimore, MD, USA, 2University of Maryland School of Pharmacy, Baltimore, MD, USA

PND50
K20
COMPARISON OF HEALTHCARE UTILIZATION BY DISEASE MODIFYING THERAPY GENERATION AMONG INDIVIDUALS DIAGNOSED WITH MULTIPLE SCLEROSIS AFTER ONE YEAR OF INITIATING THERAPY IN THE UNITED STATES
Parente A1, Sahlu I2, Sutton BS2, Petrilla A3, Clark MA2, Teigland C4
1Avalere Health LLC - An Inovalon Company, Bowie, MD, USA, 2Avalere Health, Washington, DC, USA, 3Avalere Health LLC, Washington, DC, USA, 4Avalere Health - An Inovalon Company, Bowie, MD, USA

PND51
K21
OPIOID USE AMONG PATIENTS PRESENTING WITH MIGRAINE IN THE EMERGENCY DEPARTMENT
Shah S1, Rascati KL2, Brown CM1, Khan F3, Thach A4, Desai P4
1The University of Texas at Austin, Austin, LA, USA, 2The University of Texas at Austin, Austin, TX, USA, 3Ochsner Neuroscience Institute, New Orleans, LA, USA, 4Amgen Inc., Thousand Oaks, CA, USA

PND52
K22
HEALTH TECHNOLOGY ASSESSMENT OF GENE THERAPIES FOR INHERITED GENETIC DISORDERS IN THE US AND EUROPE
Hollier-Hann G1, Cork D1, Ralston S2, Curry A2
1SIRIUS Market Access, Newcastle upon Tyne, UK, 2SIRIUS Market Access, London, UK

PND53
K23
AVAILABILITY OF REAL-WORLD EVIDENCE (RWE) TO SUPPORT ECONOMIC MODELLING IN PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS (PPMS)
Brown A1, Curry A2, Cork D1
1SIRIUS Market Access, Newcastle upon Tyne, UK, 2SIRIUS Market Access, London, UK

Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.